Sociedad Americana de Hirudoterapia

A peptide inhibitor of macrophage migration in atherosclerosis purified from the leech Whitmania pigra

Research article published in Journal of ethnopharmacology (2020)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genómica y proteómicaHu B et al. · Journal of ethnopharmacology, 2020

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Atherosclerosis has become a worldwide public health problem that seriously threatens human health. Leech is traditional Chinese medicine that can be utilized to treat cardiovascular disease. Based on the anti-atherosclerosis activity of leech hydrolysate, we separated and purified the leech peptide capable of inhibiting macrophage migration and studied the pathways of the anti-migration leech peptide. MATERIALS AND METHODS: The leech peptide capable of inhibiting macrophage migration that measured by cell migration assays from the leech Whitmania pigra was separated and purified by Q Sepharose FF strong alkaline anion exchange column chromatography, Superdex 30, Superdex peptide and G10 gel column chromatography. And the purity, molecular weight of the leech peptide was determined by high-performance liquid chromatography and high-resolution mass spectrometry. The pathways of anti-migration to macrophages of the leech peptide were studied by inhibitors, Western blotting and RT-PCR. RESULTS: We obtained a purified leech peptide with a sequence of EAGSAKELEGDPVAG from the leech Whitmania pigra. We also showed that the anti-migration to macrophages of the leech peptide was blocked by c-Jun N-terminal kinase (JNK) inhibitor and p38 mitogen-activated protein kinase (p38 MAPK) inhibitor. Moreover, the result of RT-PCR and Western blotting revealed that the leech peptide induced an increase in JNK, p38 phosphorylation and the transcription of mitogen-activated protein kinase kinase kinase 4 (MEKK4) and apoptosis signal-regulating kinase 2 (ASK2). These data indicated that the anti-migration to macrophages of the leech peptide occurred through JNK and p38 MAPK pathways. In addition, the results demonstrated that the leech peptide had no significant effect on the immunological activity of macrophages including phagocytic ability, lysozyme activity, and levels of expression of inflammatory factors. CONCLUSION: A sequence peptide was obtained from the hydrolysate of leech Whitmania pigra that inhibits macrophage migration.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsAtherosclerosisCell MovementCytokinesLeechesMAP Kinase Signaling SystemMiceMuramidasePeptidesPhagocytosisRAW 264.7 Cells

Resumen

Atherosclerosis has become a worldwide public health problem that seriously threatens human health.

Por qué esto importa para la hirudoterapia

This study purified a 15-amino-acid peptide (sequence EAGSAKELEGDPVAG) from the leech Whitmania pigra hydrolysate that inhibits macrophage migration, relevant to atherosclerosis, and characterized its mechanism through the JNK and p38 MAPK pathways. The peptide increased JNK and p38 phosphorylation and MEKK4/ASK2 transcription, while showing no significant effect on macrophage phagocytic ability, lysozyme activity, or inflammatory factor expression. For ASH's domain, this is directly relevant as identification of a bioactive leech-derived peptide with potential cardiovascular-disease-relevant anti-atherosclerotic activity. The limitation is that the work is preclinical, apparently in-vitro/cell-based with some pathway inhibitor data, and provides no in-vivo or clinical evidence of anti-atherosclerotic efficacy.

Citación

A peptide inhibitor of macrophage migration in atherosclerosis purified from the leech Whitmania pigra

Hu B et al. · Journal of ethnopharmacology, 2020

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.